You are here
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
SBC: APPLIED GENETIC TECHNOLOGIES CORPORATION Topic: N
DESCRIPTION provided by applicant Complete achromatopsia is an autosomal recessive inherited congenital disorder of retinal cone photoreceptors Patients with complete achromatopsia experience extreme light sensitivity and daytime blindness and best visual acuity under non bright light conditions is usually or worse and generally stable over time In addition to poor acuity hypersensit ...STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
Pre-clinical evaluation of DT-001, a small molecule antagonist of MD2-TLR4 for utility in the treatment of pain.SBC: Douleur Therapeutics Inc Topic: NINDS
Project Summary AbstractUpwards ofmillion individuals are afflicted by chronic pain in the US alonewithmillion of these individuals suffering from neuropathic painOn a global scalechronic pain affectsbillion individualswithwho endure lower back painFrom a clinical perspectivethe International Association for the Study of Pain approximates thatinpatients present with painand on an annual basisinpat ...STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
SBC: AMERICAN LIFE SCIENCE PHARMACEUTICALS, INC. Topic: NINDS
Project Summary Traumatic brain injuryTBIcauses detrimental behavioral dysfunctions and brain neurodegeneration butunfortunatelythere currently is no effective pharmaceutical TBI treatmentThe underlying PhaseSTTR grant is to develop a new class of TBI drugs that inhibit the protease cathepsin BGenetically deleting the cathepsin B gene in mice results in substantial behavioral and pathology improve ...STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
SBC: EIGER GROUP INTERNATIONAL, INC. Topic: NIAID
DESCRIPTION (provided by applicant): Over 150 million people worldwide are infected with the hepatitis C virus (HCV), which is an important cause of chronic liver disease. Current therapies are inadequate. Our long-term objective is to bring a new class of anti-HCV drugs to the clinic. We recently discovered and genetically validated a new target within the HCV non-structural protein NS4B, consist ...STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
SBC: SORRENTO THERAPEUTICS, INC. Topic: NIAID
DESCRIPTION (provided by applicant): In this proposal we lay out a comprehensive research plan to evaluate our passive vaccination strategies targeting Staphylococcus aureus/MRSA to prevent or treat infections associated with S. aureus/MRSA. With the emergence of highly antibiotic-resistant bacterial strains, most notably MRSA, new approaches for combating bacterial infections are desperately nee ...STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
SBC: VIROGENICS, INC. Topic: NIAID
DESCRIPTION (provided by applicant): An increasing variety of diseases are being shown to be due to immunological processes, including diabetes, and now Alzheimer's disease (AD). AD is the most prevalent age-associated disease and growing evidence suggeststhat aspects of the innate immune system play a major role its progression. Based on this evidence, we propose a new approach to the treatm ...STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
SBC: RAFT PHARMACEUTICALS LLC Topic: NIAID
PROJECT SUMMARY Asthma, characterized by airways obstruction with symptoms of wheezing, shortness of breath, chest tightness and consequently cough, remains a significant health problem. While advances in bronchodilator, corticosteroid and Th2-targeting therapy allow for well-controlled asthma in a large population of patients, subjects with severe, corticosteroid resistant asthma require frequent ...STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
SBC: MITOSCIENCES, INC Topic: NIGMS
DESCRIPTION (provided by applicant): Highly Active Anti-Retroviral Therapy (HAART) used to treat HIV/AIDS has serious side-effects, including metabolic complications from mitochondrial toxicities that can be life-threatening, and limit effectiveness and patient compliance. Adverse metabolic effects are now managed by adept clinicians who monitor patients closely for clinical symptoms and adjust t ...STTR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health
SBC: TOMEGAVAX, INC. Topic: NIAID
DESCRIPTION (provided by applicant): The goal of this project is to synthesize, based on genomic sequence information, a human cytomegalovirus (HCMV) strain with demonstrated ability to establish persistent infection in sero-positive individuals. The resulting synthetic product will form the basis for the development of attenuated HCMV vaccines. Innovative synthetic biology methods will overcome ...STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
SBC: TSRL, INC. Topic: NIAID
Abstract Bronchiectasis is a lung pathology characterized by a permanent dilation of the bronchi and is associated with a chronic cough, sputum production and recurrent respiratory infections. Cystic fibrosis (CF) is one of the best understood inherited conditions that leads to progressive bronchiectasis, chronic bacterial infection and premature mortality. Both non-CF bronchiectasis (NCFB) and CF ...STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health